<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clazosentan, an endothelin <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>, is under development by Actelion (formerly Axovan), under license from F Hoffman-La Roche, for the potential prevention of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induced by <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Results from the phase IIb portion of a phase IIb/III clinical study are expected in the first half of 2006 </plain></SENT>
</text></document>